Skip to content

VISTAGEN THERAPEUTICS, INC.: 10-Q filed 2023-11-09

What VISTAGEN THERAPEUTICS, INC. reported in its quarterly report filed 2023-11-09 (fiscal Q2 2024): 27 published measures, 78 facts as tagged in accession 0001437749-23-031293.

This filing

Form
10-Q (quarterly report)
Filed
2023-11-09
Fiscal period
fiscal Q2 2024
Accession
0001437749-23-031293 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All VISTAGEN THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-09-3042,195,800USD
At 2023-03-3121,089,200USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-09-306,550,600USD
At 2023-03-319,009,200USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-09-3035,645,200USD
At 2023-06-306,849,000USD
At 2023-03-3112,080,000USD
At 2022-09-3029,605,000USD
At 2022-06-3046,052,000USD
At 2022-03-3164,715,300USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-09-3037,608,400USD
At 2023-03-3116,637,600USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-6,587,700USD92
2023-04-01 to 2023-09-30-13,490,800USD183
2023-04-01 to 2023-06-30-6,903,100USD91
2022-07-01 to 2022-09-30-17,483,200USD92
2022-04-01 to 2022-09-30-37,259,500USD183
2022-04-01 to 2022-06-30-19,776,300USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-04-01 to 2023-09-30-14,080,500USD183
2022-04-01 to 2022-09-30-32,309,100USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-04-01 to 2023-09-3035,051,300USD183
2022-04-01 to 2022-09-30-339,500USD183

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-04-01 to 2023-09-300USD183
2022-04-01 to 2022-09-30-199,500USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-09-30-340,342,500USD
At 2023-03-31-326,851,700USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-07-01 to 2023-09-3010,042,530shares92
2023-04-01 to 2023-09-308,717,050shares183
2022-07-01 to 2022-09-306,893,708shares92
2022-04-01 to 2022-09-306,890,152shares183

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-0.66USD/shares92
2023-04-01 to 2023-09-30-1.55USD/shares183
2022-07-01 to 2022-09-30-2.54USD/shares92
2022-04-01 to 2022-09-30-5.41USD/shares183

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-07-01 to 2023-09-300USD92
2023-04-01 to 2023-09-302,500USD183
2022-07-01 to 2022-09-300USD92
2022-04-01 to 2022-09-305,500USD183

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-09-30444,300USD
At 2023-03-31507,300USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-04-01 to 2023-09-301,152,800USD183
2022-04-01 to 2022-09-301,988,600USD183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-6,780,200USD92
2023-04-01 to 2023-09-30-13,778,000USD183
2022-07-01 to 2022-09-30-17,489,300USD92
2022-04-01 to 2022-09-30-37,262,400USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-09-3039,076,200USD
At 2023-03-3117,507,400USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-09-302,909,500USD
At 2023-03-314,567,400USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-09-301,305,000USD
At 2023-03-312,473,100USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2023-07-01 to 2023-09-307,057,900USD92
2023-04-01 to 2023-09-3014,233,300USD183
2022-07-01 to 2022-09-3016,596,800USD92
2022-04-01 to 2022-09-3036,679,900USD183

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-07-01 to 2023-09-303,850,600USD92
2023-04-01 to 2023-09-308,047,800USD183
2022-07-01 to 2022-09-3012,894,500USD92
2022-04-01 to 2022-09-3028,185,800USD183

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-09-30379,943,800USD
At 2023-03-31342,892,500USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-09-302,045,000USD
At 2023-03-312,260,300USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2023-09-30292,600USD
At 2023-03-31787,400USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2023-09-301,393,300USD
At 2023-03-31802,700USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2023-09-30793,000USD
At 2023-03-31714,300USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-6,587,700USD92
2023-04-01 to 2023-09-30-13,488,300USD183
2022-07-01 to 2022-09-30-17,483,200USD92
2022-04-01 to 2022-09-30-37,254,000USD183

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-07-01 to 2023-09-303,207,300USD92
2023-04-01 to 2023-09-306,185,500USD183
2022-07-01 to 2022-09-303,702,300USD92
2022-04-01 to 2022-09-308,494,100USD183

Inspect the source

Entity
VISTAGEN THERAPEUTICS, INC. / CIK 0001411685
Captured
2026-09-20T08:01:56.841Z
SEC response SHA-256
1d0d09c7b53b173e35f99fba8d3201ca751174b9bb70167acdba04307bebca91

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001411685.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))